{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:27:14Z","timestamp":1793914034040,"version":"4.8.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012479","name":"General Research Fund of Shanghai Normal University","doi-asserted-by":"publisher","award":["17122923"],"award-info":[{"award-number":["17122923"]}],"id":[{"id":"10.13039\/501100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012479","name":"General Research Fund of Shanghai Normal University","doi-asserted-by":"publisher","award":["17103322"],"award-info":[{"award-number":["17103322"]}],"id":[{"id":"10.13039\/501100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018247","name":"GOH Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"University Grants Committee Research Grants Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201193","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T11:49:55Z","timestamp":1776685795000},"page":"201193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Engineering fratricide-resistant CCR4\/CD7 CAR T cells with enhanced safety and persistence for T cell malignancies"],"prefix":"10.1016","volume":"34","author":[{"given":"Sile","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2996-7229","authenticated-orcid":false,"given":"Wing","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201193_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105044","article-title":"Chimeric antigen receptor-based cellular therapy for T-cell malignancies","volume":"217","author":"Li","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.omton.2026.201193_bib2","article-title":"Generation of CCR4\/CD7 Bispecific CAR-T Cells Resistant to Fratricide and Exhaustion","author":"Li","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omton.2026.201193_bib3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5858\/arpa.2022-0482-OA","article-title":"Evaluation of Novel Targets, Including CC-Chemokine Receptor 4, in Adult T-Cell Acute Lymphoblastic Leukemia\/Lymphoma: A Mayo Clinic Clinical and Pathologic Study","volume":"148","author":"Khurana","year":"2024","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.omton.2026.201193_bib4","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025018600","article-title":"CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia","author":"Xu","year":"2026","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201193_bib5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1046\/j.1523-1747.2001.01456.x","article-title":"Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (S\u00e9zary syndrome)","volume":"117","author":"Vonderheid","year":"2001","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omton.2026.201193_bib6","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/bloodadvances.2025017573","article-title":"CAR T cells targeting CCR4 selectively deplete human Tregs ex vivo and in vivo","volume":"10","author":"Tilsed","year":"2026","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201193_bib7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","article-title":"CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?","volume":"9","author":"Maciocia","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201193_bib8","article-title":"Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA's conclusions from the evaluation of 38 suspected cases","author":"Berg","year":"2025","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2026.201193_bib9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/sj.cdd.4400825","article-title":"The CD7(-) subset of CD4(+) memory T cells is prone to accelerated apoptosis that is prevented by interleukin-15 (IL-15)","volume":"8","author":"Rappl","year":"2001","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.omton.2026.201193_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1309\/48KC17WAU69BTBXQ","article-title":"Expression of T\/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases","volume":"120","author":"Chu","year":"2003","journal-title":"Am. J. Clin. Pathol."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992600069X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992600069X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:22:46Z","timestamp":1793913766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032992600069X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S295032992600069X"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201193","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering fratricide-resistant CCR4\/CD7 CAR T cells with enhanced safety and persistence for T cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201193"}}